Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$69.95
-1.1%
$70.34
$61.24
$87.68
$219.45B0.385.21 million shs6.30 million shs
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
$29.06
-0.5%
$29.08
$10.53
$43.15
$1.27BN/A818,447 shs6.35 million shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$13.48
-1.8%
$14.84
$8.24
$18.38
$894.86M-0.17532,189 shs2.90 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
-1.14%-6.01%+0.39%-6.65%-10.80%
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
0.00%0.00%0.00%0.00%0.00%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-1.82%-5.87%-19.09%-20.09%+14.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.8796 of 5 stars
2.65.01.70.02.70.01.3
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.8121 of 5 stars
3.43.00.00.02.04.20.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
3.13
Buy$85.0021.52% Upside
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
0.00
N/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.75
Moderate Buy$32.25139.24% Upside

Current Analyst Ratings Breakdown

Latest AZN, MLYS, and CINC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00
6/10/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$15.00
5/14/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$48.00
5/13/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
4/15/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
4/2/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $42.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.01$6.22 per share11.24$13.18 per share5.31
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
N/AN/AN/AN/A($1.74) per shareN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$3.84 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.4928.0913.991.3014.14%33.14%12.83%7/24/2025 (Estimated)
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
-$50.37M-$17.28N/AN/AN/AN/A-33.03%-27.21%N/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)

Latest AZN, MLYS, and CINC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$1.02-$0.79+$0.23-$0.79N/AN/A
4/29/2025Q1 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10$1.24+$0.14$0.93$13.71 billion$13.59 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$2.062.94%N/A82.73%N/A
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
N/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.65
0.90
0.70
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
N/A
51.96
51.96
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/A
26.48
26.48

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
99.15%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
15.60%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
25.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
CinCor Pharma, Inc. stock logo
CINC
CinCor Pharma
1543.76 million36.94 millionNot Optionable
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2865.18 million48.52 millionOptionable

Recent News About These Companies

Equities Analysts Offer Predictions for MLYS Q2 Earnings
Mineralys Therapeutics, Inc. stock logo
Research Analysts Issue Forecasts for MLYS Q2 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$69.95 -0.81 (-1.14%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$69.82 -0.13 (-0.18%)
As of 06/20/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

CinCor Pharma stock logo

CinCor Pharma NASDAQ:CINC

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$13.48 -0.25 (-1.82%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$13.48 -0.01 (-0.04%)
As of 06/20/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.